Clostridium Bacteria: The Team of Microscopic Oncologists

Behboodi, Rosa; Saadati Partan, Arman; Meidaninikjeh, Sepideh; Morvarid, Yasamin; Hosseininia, Haniyeh Sadat; Sayhinouri, Maryam; Shirinsokhan, Armaghan; Javadi, Sahar; Ebrahimi Sadrabadi, Amin; Jalili, Arsalan

Volume 15, Issue 4 (September 2023 2023) Iranian Journal of Blood and Cancer 2023, 15(4): 178-202 | Back to browse issues page

Mendeley

Zotero

RefWorks

Behboodi R, Saadati Partan A, Meidaninikjeh S, Morvarid Y, Hosseininia H S, Sayhinouri M, et al . Clostridium Bacteria: The Team of Microscopic Oncologists. Iranian Journal of Blood and Cancer 2023; 15 (4) :178-202
URL: http://ijbc.ir/article-1-1405-en.html

Clostridium Bacteria: The Team of Microscopic Oncologists

Rosa Behboodi¹, Arman Saadati Partan², Sepideh Meidaninikjeh³, Yasamin Morvarid⁴, Haniyeh Sadat Hosseininia⁵, Maryam Sayhinouri⁶, Armaghan Shirinsokhan⁷, Sahar Javadi⁸, Amin Ebrahimi Sadrabadi⁹, Arsalan Jalili ^*¹⁰

1- Jawaharlal Nehru Technological University Hyderabad, Hyderabad, India
2- Department of Microbiology, Islamic Azad University, Karaj Branch, Karaj, Iran
3- Department of Microbiology, Faculty of Biological Science, Alzahra University, Tehran, Iran
4- Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
5- Department of Cellular and Molecular Biology, Faculty of Advanced Medical Science, Tehran Islamic Azad University of Medical Sciences, Tehran, Iran
6- Department of Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
7- Department of Biology, Faculty of Sciences, Rasht Branch, Islamic Azad University, Rasht, Iran
8- Department of Microbiology, Faculty of Biological Sciences, Islamic Azad University, North Tehran Branch, Tehran, Iran
9- Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACER, Tehran, Iran
10- Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACER, Tehran, Iran , Jalili.arsalan@yahoo.com

Abstract: (46 Views)

As we approach the year 2023, the global rise in cancer mortality remains a pressing concern. Recent studies have demonstrated the remarkable potential of bacteria in combating cancer by stimulating the immune system. Exciting evidence suggests that bacterial therapy can revolutionize both the treatment and diagnosis of tumors. To effectively classify and treat tumors, the introduction of obligate or optional anaerobic bacteria into solid tumors may be necessary. Notably, certain strains of Clostridium have proven to be particularly effective in cancer treatment. A fascinating natural phenomenon lies in the ability of Clostridium spores to infiltrate tumors and selectively germinate in hypoxic regions within dense tumors upon injection into a vein. This bacterial invasion directly eliminates tumor cells by enhancing the presence of tumor-specific antigens, enabling the immune system to recognize and attack cancerous cells. Although these bacteria do not directly destroy tumor cells, their activation of the immune system holds great promise for eradicating them. Currently, an extensive range of bacteria is employed for cancer treatment, designing bacteria-carrying pharmaceutical compounds, and facilitating radiotherapy or radiation therapy. Additionally, genetic manipulation techniques can enable bacteria to specifically target tumor tissue and inhibit angiogenesis. In this comprehensive review, we delve into the potential advantages of utilizing Clostridium bacteria in cancer medications. Specifically, we explore the abilities of Clostridium perfringens and Clostridium novi to induce angiogenesis, provoke immune responses, and operate within oxygen-deprived environments.

Keywords: Clostridium, Cancer, Tumor, Cancer-fighting bacteria, Bacterial therapy

Full-Text [PDF 1178 kb] (57 Downloads)

: Review Article | Subject: Adults Hematology & Oncology
Received: 2023/06/21 | Accepted: 2023/08/12 | Published: 2023/09/17

Send email to the article author

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb